A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
Platinum(IV) complexes have the potential to overcome several limitations and reduce adverse effects of platinum-based cancer therapy. Resistance to clinically approved platinum(II) drugs is, at least in part, associated with elevated levels of glutathione. Here, the authors report on an oxaliplatin...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-04-01
|
| Series: | Communications Chemistry |
| Online Access: | https://doi.org/10.1038/s42004-022-00661-z |
| _version_ | 1818066738162434048 |
|---|---|
| author | Philipp Fronik Michael Gutmann Petra Vician Mirjana Stojanovic Alexander Kastner Petra Heffeter Christine Pirker Bernhard K. Keppler Walter Berger Christian R. Kowol |
| author_facet | Philipp Fronik Michael Gutmann Petra Vician Mirjana Stojanovic Alexander Kastner Petra Heffeter Christine Pirker Bernhard K. Keppler Walter Berger Christian R. Kowol |
| author_sort | Philipp Fronik |
| collection | DOAJ |
| description | Platinum(IV) complexes have the potential to overcome several limitations and reduce adverse effects of platinum-based cancer therapy. Resistance to clinically approved platinum(II) drugs is, at least in part, associated with elevated levels of glutathione. Here, the authors report on an oxaliplatin-based platinum(IV) prodrug, which releases L-buthionine-S,R-sulfoximine, an inhibitor of the rate-limiting enzyme in glutathione biosynthesis, to circumvent glutathione-based resistance mechanisms. |
| first_indexed | 2024-12-10T15:12:33Z |
| format | Article |
| id | doaj.art-99d429aedc2744caa3be3e3e739e2c42 |
| institution | Directory Open Access Journal |
| issn | 2399-3669 |
| language | English |
| last_indexed | 2024-12-10T15:12:33Z |
| publishDate | 2022-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Chemistry |
| spelling | doaj.art-99d429aedc2744caa3be3e3e739e2c422022-12-22T01:43:53ZengNature PortfolioCommunications Chemistry2399-36692022-04-015111310.1038/s42004-022-00661-zA platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistancePhilipp Fronik0Michael Gutmann1Petra Vician2Mirjana Stojanovic3Alexander Kastner4Petra Heffeter5Christine Pirker6Bernhard K. Keppler7Walter Berger8Christian R. Kowol9University of Vienna, Faculty of Chemistry, Institute of Inorganic ChemistryCenter of Cancer Research and Comprehensive Cancer Center, Medical University of ViennaCenter of Cancer Research and Comprehensive Cancer Center, Medical University of ViennaCenter of Cancer Research and Comprehensive Cancer Center, Medical University of ViennaUniversity of Vienna, Faculty of Chemistry, Institute of Inorganic ChemistryCenter of Cancer Research and Comprehensive Cancer Center, Medical University of ViennaCenter of Cancer Research and Comprehensive Cancer Center, Medical University of ViennaUniversity of Vienna, Faculty of Chemistry, Institute of Inorganic ChemistryCenter of Cancer Research and Comprehensive Cancer Center, Medical University of ViennaUniversity of Vienna, Faculty of Chemistry, Institute of Inorganic ChemistryPlatinum(IV) complexes have the potential to overcome several limitations and reduce adverse effects of platinum-based cancer therapy. Resistance to clinically approved platinum(II) drugs is, at least in part, associated with elevated levels of glutathione. Here, the authors report on an oxaliplatin-based platinum(IV) prodrug, which releases L-buthionine-S,R-sulfoximine, an inhibitor of the rate-limiting enzyme in glutathione biosynthesis, to circumvent glutathione-based resistance mechanisms.https://doi.org/10.1038/s42004-022-00661-z |
| spellingShingle | Philipp Fronik Michael Gutmann Petra Vician Mirjana Stojanovic Alexander Kastner Petra Heffeter Christine Pirker Bernhard K. Keppler Walter Berger Christian R. Kowol A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance Communications Chemistry |
| title | A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance |
| title_full | A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance |
| title_fullStr | A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance |
| title_full_unstemmed | A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance |
| title_short | A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance |
| title_sort | platinum iv prodrug strategy to overcome glutathione based oxaliplatin resistance |
| url | https://doi.org/10.1038/s42004-022-00661-z |
| work_keys_str_mv | AT philippfronik aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT michaelgutmann aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT petravician aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT mirjanastojanovic aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT alexanderkastner aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT petraheffeter aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT christinepirker aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT bernhardkkeppler aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT walterberger aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT christianrkowol aplatinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT philippfronik platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT michaelgutmann platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT petravician platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT mirjanastojanovic platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT alexanderkastner platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT petraheffeter platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT christinepirker platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT bernhardkkeppler platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT walterberger platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance AT christianrkowol platinumivprodrugstrategytoovercomeglutathionebasedoxaliplatinresistance |